券商中国记者注意到，公募基金重仓的晶泰控股、固生堂、医渡科技、讯飞医疗科技、云知声等港股AI医疗 公司，纷纷在寻找第二增长曲线，而出海则成为这些公司获得成长弹性的关键因素。例如，头部基金集体布局 的晶泰控股出海业务频传捷报，公司日前又宣布其通过AI技术帮助一家药企获得澳大利亚的临床试验批准， 截至今年6月末，晶泰控股已是华夏基金、招商基金、富国基金等头部公募的重仓股。 银华基金重仓的医渡科技近日也披露已开展国际化业务，包括AI辅助诊疗在内的产品服务已开始进入新加 坡、文莱等国家。根据医渡科技日前披露的2025年度财报（2024年4月至2025年3月），按地区分布看，公司海 外市场收入增长速度远超国内，其间来自文莱的收入规模已超过1亿元，文莱市场对医渡科技的收入贡献占比 达到14.36%。 对偏爱AI医疗的基金经理而言，商业化落地此前一直是AI医疗赛道需要解决的问题，但随着越来越多的AI医 疗公司强化拓展海外收入，相关公司的估值也变得水涨船高，甚至反超QDII基金重仓的美股对标公司。对 此，多位基金经理判断，国内AI医疗仍处于从0到1的拓展期，未来通过快速商业化落地，将有望逐步解决高 估值问题。 出海逻辑延伸至 ...

Core Insights - The event held in Mianyang, Sichuan, focused on "disruptive technologies and future industrial development," featuring discussions on cutting-edge fields such as embodied intelligent robots, nuclear medicine, and materials science [1] - The "Disruptive Technology Industrialization Index Report (2025)" was released, aiming to scientifically assess the transition of disruptive technologies from laboratory to application, providing strategic insights for future industrial trends and resource allocation [1] Disruptive Technology Industrialization Index (DTII) - The DTII was created to quantify the complex process of transforming disruptive technologies from ideas to products and industries, filling a gap in decision-making support for governments, markets, and enterprises [2] - The index features a unique "Five Forces" evaluation framework, which includes: 1. Technological Innovation Power 2. Industrial Development Power 3. Ecological Support Power 4. Future Growth Power 5. Market Transformation Power [2][3] Key Findings - The report identifies three critical findings regarding the core mechanisms and driving forces of disruptive technology industrialization [4] - A significant breakthrough is the revelation of the decisive role of the "R&D market" in early industrialization stages, particularly for technologies like high-temperature superconductors and controlled nuclear fusion, which often lack mature commercial products [4] - The report emphasizes that regions like Beijing, the Yangtze River Delta, and the Guangdong-Hong Kong-Macao Greater Bay Area serve as irreplaceable "innovation sources," creating a self-accelerating effect through the synergy of technological innovation, industrial development, and ecological support [4] Future Developments - The DTII will continue to evolve by integrating real-time data and AI analysis, enhancing dynamic monitoring and predictive capabilities, and expanding its coverage to strengthen international comparisons [5] - The goal is to transform the index from an assessment tool into a strategic navigation platform, acting as a "barometer" and "catalyst" for deep integration of technological and industrial innovation, contributing to the construction of a strong technological nation [5]

Group 1 - The Shanghai Future Industry Fund has successfully completed an expansion, increasing its scale from 10 billion to 15 billion yuan, with 8 billion yuan already paid in [1] - The fund has invested in cutting-edge fields such as controllable nuclear fusion, quantum computing, AI for science, and brain-computer interfaces [1] - The next steps for the fund include focusing on disruptive innovation and early-stage investments in frontier platform technologies, while building a collaborative network of innovative resources [1] Group 2 - The fund aims to leverage fiscal funds to stimulate investment and collaborate with more excellent sub-funds and projects through a comprehensive "investment + ecosystem" approach [1] - The initiative supports the construction of Shanghai as an international science and technology innovation center, injecting strong momentum into the future industrial development of Shanghai [1]

9月28日，主题为"智能创新脑联未来"的脑机接口创新技术赋能产业应用会议在南京市栖霞区举行。会议由栖霞区人民政府、南京经济技术开发区管委 会、仙林大学城管委会、江苏省人民医院、南京市生物医药产业攻坚推进办公室联合主办。 省级平台落子栖霞，构筑脑机接口创新核心引擎 当前，全球科技革命与产业变革加速演进，脑机接口技术作为融合了神经科学、信息科技、材料工程等多学科智慧的尖端领域，近年来在基础理论突破和 实际应用拓展上均取得了令人瞩目的成就，尤其在医疗健康、智能康复、人机交互等方面展现出巨大的应用潜力和广阔的发展前景。 会议现场，江苏脑机接口研究院正式启动。该研究院定位为省级脑机接口共性技术和产业服务平台，由江苏省人民医院、栖霞区人民政府、仙林大学城管 委会联合多方共建，旨在聚焦脑机接口科技创新和产业创新关键环节，推动脑机接口技术创新、服务产业发展和临床转化。据悉，该平台是今年全国立项 金额最大的脑机接口公共服务平台项目，也是唯一以临床为牵引的"产学研用"枢纽。 江苏脑机接口研究院落子栖霞，得益于其独特的"三区联动"优势。近年来，栖霞区聚焦智能制造、生物医药等主导产业，形成了大学城创新圈、行政区孵 化圈、经开区产业圈 ...

人民财讯9月28日电，9月28日，上海未来产业基金宣布，其近日顺利完成扩募，规模由100亿元增至150 亿元，并已实缴到位80亿元。目前，上海未来产业基金已经在可控核聚变、量子计算、Al for Science、 脑机接口等前沿领域布局了一批优秀项目。下一步，上海未来产业基金将持续聚焦颠覆式创新、前沿平 台性技术等未来领域早期布局，联动上海未来启点社区构建创新资源协同网络，充分发挥财政资金撬动 效应，与更多优秀的子基金及项目开展"投资+生态"的全方位合作，助力上海国际科创中心建设，为上 海未来产业发展注入强劲动力。 ...

Group 1 - The brain-computer interface (BCI) industry is projected to reach USD 7.63 billion by 2029, driven by policy support and demand from medical conditions such as stroke and ALS [4] - The industry is entering a "policy-research-application" closed loop, with a clearer commercialization path [4] - Recommended companies in the BCI sector include Xiangyu Medical, Weisi Medical, Chengyitong, Mailande, Aipeng Medical, and Sanbo Neurosurgery [4] Group 2 - Mengke Pharmaceutical plans to issue 164 million shares at a price of 6.3 CNY per share, raising up to 1.033 billion CNY, which will make Haiqing Pharmaceutical the controlling shareholder [9] - The projected net profit for Mengke Pharmaceutical from 2025 to 2027 is estimated to be -241 million, -190 million, and -99 million CNY respectively, maintaining a "buy" rating [9] Group 3 - The cobalt export quota system in the Democratic Republic of the Congo (DRC) is expected to lead to a significant reduction in cobalt supply, positively impacting cobalt prices [13] - The DRC accounted for 76.3% of global cobalt production in 2024, and the supply constraints are likely to benefit companies like Huayou Cobalt and Luoyang Molybdenum [13] Group 4 - China Railway Assembly reported stable revenue growth and improved cash flow in H1 2025, with a projected net profit of 2 million, 44 million, and 68 million CNY for 2025 to 2027 [16] - The company maintains an "overweight" rating based on its financial performance [16] Group 5 - The dividend yield of Midea Group has exceeded 7%, indicating a potential bottoming out, with a projected profit of 33 billion CNY for 2025 and a 52% cash dividend rate [18] - The company maintains a "buy" rating with a target price of 54.10 CNY [18] Group 6 - The real estate market in Shanghai is experiencing increased transaction volumes due to favorable policies, with a 62.5% increase in daily average transactions post-policy implementation [29] - The top three companies in Shanghai's new home transaction value from January to August 2025 are Poly Developments, China Merchants Shekou, and China Resources Land [29] Group 7 - PetroChina has signed a USD 359 million contract with Total for the design, procurement, supply, construction, and commissioning of a project in Iraq, with projected net profits of 909 million, 1.099 billion, and 1.315 billion CNY from 2025 to 2027 [33] - The company maintains an "overweight" rating for both its A-shares and H-shares [33]

"一想到永远都得坐轮椅，感觉天塌了。"聂鹏说，身体长期不动，肌肉日渐萎缩，产生了尿路感染、静 脉血栓等并发症，每个月都要去医院打几次消炎针。 身体失能、心态失衡，像不少截瘫患者一样，聂鹏把自己"锁"在家中，"除了坐着就是躺着，身体越来 越差。" 2017年，程天科技落地杭州未来科技城人工智能小镇，主攻外骨骼的研发和应用。"外骨骼，看上去像 绑在人身上的'铁架子'，但实际上是一种集信息技术、移动计算等尖端技术于一身的可穿戴机器人系 统。"程天科技创始人王天说，比如王先生用的外骨骼机器人，腿部的力量传感器能够识别使用者的动 作意图，并在辅助运动装置的驱动下，按照健全人的行走特征，帮患者站起来、走起来。 "十四五"亮点 "十四五"时期，全国已就业残疾人数量达901万，城乡新增残疾人就业人数累计达231万 "绑带系紧，抓好握把，发力，起——"浙江杭州程天科技发展有限公司的康复中心内，借助外骨骼机器 人，在轮椅上坐了10多年的残疾人王先生再次站了起来，周围的工作人员爆发出掌声与欢呼声。 "为他高兴，真的。我也为自己高兴！"测试工程师聂鹏的眼眶湿润了，他和王先生一样，也坐在轮椅 上。 10多年前，作为汽修工人的聂鹏，因事 ...

Core Insights - The article highlights the positive impact of exoskeleton robots on rehabilitation for individuals with disabilities, emphasizing the personal growth and technological engagement of a disabled individual who transitioned from a user to a developer of such technology [2] Group 1: Technological Advancements - Exoskeleton devices are becoming more sophisticated, with the ability to capture patients' intentions and assist in walking, indicating a significant advancement in rehabilitation technology [2] - The introduction of brain-computer interface technology is being tested, which could further enhance the capabilities of exoskeletons [2] Group 2: Social Impact - There is an increasing societal acceptance and support for individuals with disabilities, as evidenced by improved accessibility features in urban environments, such as in Hangzhou [2] - The article reflects a growing recognition and appreciation for the contributions of disabled individuals in technology development, fostering a sense of community and empowerment [2]

Core Viewpoint - The National Medical Products Administration (NMPA) has approved the implementation of the first industry standard for brain-computer interface (BCI) medical devices in China, set to take effect on January 1, 2024, positioning China as a leader in this field internationally [1][6]. Summary by Relevant Categories Definition and Scope of BCI - The new standard defines "brain-computer interface" as a medical device capable of real-time decoding neural signals from the central nervous system, facilitating bidirectional information exchange between patients and external devices to improve or replace certain physiological functions [1][3][5]. Standardization and Regulatory Support - The standard provides a unified language for product development, production inspection, registration review, and regulation, covering core terms related to BCI medical devices, including paradigm types, signal forms, and signal processing [3]. - NMPA is expediting the establishment of multiple related standards and supportive policies to foster rapid development in the BCI medical device industry, with three additional standards already in the pipeline [9][11]. Market Growth and Future Projections - The BCI market in China is projected to exceed 6 billion yuan by 2028, with an estimated compound annual growth rate (CAGR) of 17.7% from 2024 to 2028. The global market for BCI applications in healthcare is expected to reach $40 billion by 2030 and $145 billion by 2040 [12].

Core Viewpoint - The company, Yingkang Life, emphasizes its commitment to clinical value and long-term strategy in the fields of brain-computer interfaces and rehabilitation robotics, focusing on technological maturity and business synergy in its clinical explorations and collaborations [1] Group 1: Strategic Focus - The company is strategically focused on the entire industry chain of tumor pre-diagnosis and treatment, consistently communicating this strategy through regular reports, announcements, and investor engagement activities [1] - The management plans to leverage resources from the Haier ecosystem to steadily enhance core capabilities and actively seek frontier collaboration opportunities that align with its strategy [1] Group 2: Operational Approach - The company prioritizes the maturity of technology and commercial viability in its innovation efforts, reflecting the high technical barriers and stringent regulatory requirements of the medical industry [1] - The management will continue to optimize team structure and attract professional talent to drive high-quality development [1] Group 3: Market Outlook - The company expresses strong confidence in the long-term prospects of the health industry and aims to reward investors' trust through solid operational performance [1]